Navigation Links
Dr. Gail Naughton Speaks on Histogen's Business Plan and the Rise of Bioaesthetic Medicine during Commercial Translation of Regenerative Medicine
Date:11/17/2008

ExCeltrix Preliminary Oncology Data Presented for the First Time

San Diego, CA (PRWEB) November 17, 2008 -- Dr. Gail Naughton, CEO of Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today addressed attendees at the 6th Annual Commercial Translation of Regenerative Medicine conference, taking place November 17-18, 2008 in London.

Dr. Naughton examined the growing bioaesthetic medicine industry, as well as shared Histogen's business plan for near-term regenerative medicine products focused on anti-aging and post-resurfacing treatments, at the event.

"Due to long timelines in the development of medical devices and pharmaceuticals, Histogen is taking advantage of the unique opportunity to enter the growing $4.5 billion global aesthetic medicine market, to help generate early revenues and allow the Company to continue to fund the development and clinical evaluation of future products," said Dr. Lawrence Rheins, President of Histogen Aesthetics LLC. "The newly formed Histogen Aesthetics division addresses this market, offering scientific and clinically-proven products based on Histogen's proprietary technology, for skin hair and nail products dispensed by physicians."

Histogen Aesthetics' initial product line will be focused on ReGenicaTM, the Company's unique complex made up of the naturally secreted growth factors, antioxidants and other synergistic bio-products that are produced by newborn fibroblasts. Product launches in the areas of anti-aging and post-resurfacing are scheduled for early 2009.

In addition to ReGenica, Dr. Naughton spoke to Histogen's plan to bring their human embryonic-like extracellular matrix product, ExCeltrixTM, into clinical trials as an injectable for wrinkles and deep furrows.

"ExCeltrix, Histogen's unique human extracellular matrix which is grown in a simulated embryonic environment, is currently being evaluated for a variety of applications, from dermal fillers to implant coatings," said Dr. Robert Kellar, VP of Research and Development at Histogen. "Intriguing preliminary results from ongoing ExCeltrix research shows promise of in the field of oncology."

Dr. Naughton presented data for the first time supporting the ability of ExCeltrix to diminish or eliminate tumor load in preclinical trials. Studies were performed with three rapidly growing human tumor cell lines: melanoma, adenocarcinoma, and glioma. Cancer cells were either mixed with ExCeltrix or delivered alone in two preclinical models. In the CAM model (chollioallantoic membrane) tumor mass was significantly reduced by the presence of ExCeltrix. In the nude mouse model, cells with ExCeltrix showed little to no tumor growth, in comparison to the control which did form palpable tumors.

Dr. Gail Naughton has spent more than 15 years extensively researching the tissue engineering process, and holds more than 90 patents in the field. Dr. Naughton founded Histogen in 2007, and currently serves as Chief Executive Officer and Chairman of the Board for the Company, in addition to her position as Dean of the College of Business at San Diego State University.

About Histogen
Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products that do not contain embryonic stem cells or animal components. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn fibroblasts are encouraged to naturally produce the vital proteins and growth factors from which the company has developed its rich product portfolio. Histogen has two product families - ExceltrixTM, Histogen's human Extracellular Matrix (ECM) and ReGenicaTM, Histogen's proprietary liquid formula. For more information, please visit http://www.histogeninc.com.

###

Read the full story at http://www.prweb.com/releases/Histogen/CommTranslations/prweb1620614.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. Frost & Sullivan Awards Baxters BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award
2. Confirmation of HGT Business Day - 18th November 2008
3. PointCross Releases Catalyst for Building Business-Ready SharePoint Solutions in 1/10th the Time
4. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
5. South Africas Minister of Minerals and Energy Welcomes Denham Capital Investment in BioTherm Energy to Develop Power Generation Business
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
8. ThromboGenics N.V.: Business Update
9. Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
10. Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
11. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ... April 18, 2017 , ... A number of new instruments have recently emerged ... of the Protein and Cell Analysis Education Webinar Series , will focus on ... in current and future applications. , Many flow cytometers have unique capabilities and ...
(Date:4/19/2017)... Waltham, MA (PRWEB) , ... April 19, 2017 ... ... of a $1.5M Series A-1 financing round. This event adds to several other ... establishment of its’ Executive and Scientific Teams. , ThermaGenix will use ...
(Date:4/19/2017)... 2017  As a Bronze Sponsor of ... ,  Proove® Biosciences, Inc. announces the first-ever ... lifestyle factors to accurately predict prescription opioid abuse. In ... California (USC), the Interventional Pain Institute in ... showing that Proove Opioid Risk® accurately identifies patients ...
(Date:4/18/2017)... ... April 18, 2017 , ... METTLER TOLEDO Process ... concentration levels and vice-versa. , One of the key applications for the measurement ... control or monitoring. The principle of this analytical method is based on pure ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
Breaking Biology News(10 mins):